ANI Pharmaceuticals (NASDAQ:ANIP) Insider Sells $30,858.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) insider Christopher Mutz sold 417 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $74.00, for a total value of $30,858.00. Following the completion of the sale, the insider owned 103,508 shares of the company’s stock, valued at approximately $7,659,592. This trade represents a 0.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Christopher Mutz also recently made the following trade(s):

• On Friday, February 20th, Christopher Mutz sold 5,323 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $78.02, for a total value of $415,300.46.

ANI Pharmaceuticals Trading Down 2.1%

NASDAQ:ANIP opened at $74.04 on Friday. ANI Pharmaceuticals, Inc. has a 12 month low of $56.71 and a 12 month high of $99.50. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of 22.04 and a beta of 0.52. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. The company’s 50 day moving average is $79.66 and its 200-day moving average is $85.93.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares during the last quarter. Global Alpha Capital Management Ltd. increased its holdings in shares of ANI Pharmaceuticals by 17.2% during the 2nd quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock worth $56,251,000 after purchasing an additional 126,500 shares during the period. State Street Corp raised its position in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after buying an additional 15,496 shares during the last quarter. UBS Group AG raised its position in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares during the last quarter. Finally, Tang Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 51.6% in the fourth quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock valued at $38,005,000 after buying an additional 163,937 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of recent analyst reports. Barclays assumed coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target for the company. Guggenheim lifted their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $103.43.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.